- Home
- LCW vs LCTX Comparison
LCW vs LCTX Comparison
Compare LCW & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCW
- LCTX
- Stock Information
- Founded
- LCW 2021
- LCTX 1990
- Country
- LCW United States
- LCTX United States
- Employees
- LCW N/A
- LCTX N/A
- Industry
- LCW Blank Checks
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LCW Finance
- LCTX Health Care
- Exchange
- LCW Nasdaq
- LCTX Nasdaq
- Market Cap
- LCW 165.8M
- LCTX 165.6M
- IPO Year
- LCW 2021
- LCTX N/A
- Fundamental
- Price
- LCW $11.00
- LCTX $0.93
- Analyst Decision
- LCW
- LCTX Strong Buy
- Analyst Count
- LCW 0
- LCTX 3
- Target Price
- LCW N/A
- LCTX $5.67
- AVG Volume (30 Days)
- LCW 81.6K
- LCTX 309.4K
- Earning Date
- LCW 01-01-0001
- LCTX 11-07-2024
- Dividend Yield
- LCW N/A
- LCTX N/A
- EPS Growth
- LCW N/A
- LCTX N/A
- EPS
- LCW N/A
- LCTX N/A
- Revenue
- LCW N/A
- LCTX $6,186,000.00
- Revenue This Year
- LCW N/A
- LCTX N/A
- Revenue Next Year
- LCW N/A
- LCTX $119.00
- P/E Ratio
- LCW N/A
- LCTX N/A
- Revenue Growth
- LCW N/A
- LCTX N/A
- 52 Week Low
- LCW $10.60
- LCTX $0.77
- 52 Week High
- LCW $11.03
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- LCW 57.79
- LCTX 54.24
- Support Level
- LCW $10.99
- LCTX $0.83
- Resistance Level
- LCW $11.01
- LCTX $0.94
- Average True Range (ATR)
- LCW 0.01
- LCTX 0.05
- MACD
- LCW -0.00
- LCTX 0.01
- Stochastic Oscillator
- LCW 66.67
- LCTX 82.50
About LCW Learn CW Investment Corporation
Learn CW Investment Corp is a blank check company. It is formed for the purpose of effecting a merger, consolidation, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.